Kura Oncology Logo
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
December 08, 2020 20:22 ET | Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Announces Commencement of Public Offering of Common Stock
December 07, 2020 16:01 ET | Kura Oncology, Inc.
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
December 05, 2020 12:30 ET | Kura Oncology, Inc.
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a...
Kura Oncology Logo
Kura Oncology to Host Virtual Investor Event on December 5, 2020
November 24, 2020 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Reports Third Quarter 2020 Financial Results
November 05, 2020 07:30 ET | Kura Oncology, Inc.
– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract...
Kura Oncology Logo
Kura Oncology to Participate in Three Upcoming Investor Conferences
November 04, 2020 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology to Report Third Quarter 2020 Financial Results
October 29, 2020 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma
October 26, 2020 07:30 ET | Kura Oncology, Inc.
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2...
Kura Oncology Logo
Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
October 07, 2020 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology to Participate in Two Upcoming Investor Conferences
September 08, 2020 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...